UAA.png
Congress Passes Bills Making Major Investments in Alzheimer’s
March 23, 2024 10:15 ET | UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
March 14, 2024 17:50 ET | The Rosen Law Firm PA
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
UAA.png
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
March 08, 2024 07:55 ET | UsAgainstAlzheimer's
WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...
Emergen logo.png
Smart Pills Market Size Worth USD 1.84 Billion in 2032 | Emergen Research
January 04, 2024 07:43 ET | Emergen Research
Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global smart pills market size was USD 0.60 Billion in 2022 and is expected to register a   rapid revenue CAGR of 12.0% during the forecast period...
July 30, 2021 - ROSEN LOGO.jpg
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm – BCLI
January 01, 2024 13:55 ET | The Rosen Law Firm PA
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
NO16 NEUROONE LOGO_RGB.png
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
December 11, 2023 08:00 ET | NeuroOne Medical Technologies Corp
First FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control; Marks the Company’s third...
Logo.jpg
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
December 04, 2023 09:30 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
November 26, 2023 21:36 ET | The Rosen Law Firm PA
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 19, 2023 23:19 ET | The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
July 30, 2021 - ROSEN LOGO.jpg
OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 16, 2023 14:09 ET | The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...